Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Robert Mayo who wrote (330)	1/15/1999 8:09:00 PM
From: aknahow	Read Replies (1) \| Respond to of 712

I had problems getting the site to load. Is it really up yet?

To: Robert Mayo who wrote (330)	1/22/1999 5:45:00 PM
From: aknahow	Respond to of 712

I called IR today to ask if Cor would put out some release on how its' oral anti platelet drug differed if it does from Monsantos. They intend to wait for more data from Monsanto which might be forthcoming in a March meeting. I pointed out that that the scientist at Cor probably already know enough about the Monsanto approach and how it differs from Cors' to make some comment now. By March the damage is done. I still find the site non accessible. It apparently has shockwave and other thinks that don't load unless one has specific software. I think they should have a content oriented site and gave an example of the XOMA site. But I could not give Jackie examples of what fancy things might be slowing down loading, since I can't get into the site. They are so proud of their annual report, it makes me sick. I happened to look at it again and it says it the, "seventh in a series of educational reports." Expensive, self-serving and not oriented towards investors. Am certain the medical profession already understands the areas discussed. I mentioned that it was reported that their H & Q presentation also was considered boring because of its' "educational" approach. Cor could certainly use some improvement in its' understanding of shareholder relations, they are quite dismissive in tone and one gets the sense that they have no intention of ever considering anything a shareholder says. This does not mean I do not like the stock, only that I think they have a long way to go in I.R.